CervoMed 在 AAIC 2026 公布 Neflamapimod 治疗路易体痴呆的新临床、血浆生物标志物及影像学数据

美股速递
Jul 14

CervoMed 在 2026 年阿尔茨海默病协会国际会议上,公布了其药物 Neflamapimod 用于治疗路易体痴呆的最新研究成果。此次公布的数据涵盖了关键的临床疗效指标、创新的血浆生物标志物分析以及先进的神经影像学发现,为评估该疗法的潜力提供了多维度的证据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10